Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: The clinical significance of adenomatous polyposis coli (APC) and catenin Beta 1 (CTNNB1) genetic aberrations in patients with melanoma

Fig. 2

Overall survival (OS) analysis of patients with metastatic melanoma who have received immunotherapies at some point during the natural history of their disease according to the APC/CTNNB1 genetic aberration status (combined UNC-CH/Vanderbilt/CPMRI cohort). Please note that one subject from the APC/CTNNB1-mutant group was lost to follow-up

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us